INTRODUCTION Lymphoid cells of the immune system can be divided into two functional compartments. The thymus-derived
This work was presented in part at the Annual Meeting of the American Society of Hematology, December 1971, San Francisco, Calif. Received for publication 18 October 1971 and in revised form 3 February 1972. T 1 lymphocyte appears to be responsible for cell-mediated immunity; the bone marrow-derived B lymphocyte is responsible for antibody production (1) . These two populations of cells can be distinguished by the presence of different membrane receptors and differentiation antigens. In the mouse, the T lymphocyte can be identified by the presence of the 0-iso-antigen (2); in man, no satisfactory marker of the T lymphocyte has as yet been identified. The B lymphocyte, in most species studied, can be identified by the presence of easily detectable surface immunoglobulin (3) . Most B lymphocytes also bear a recently described receptor for antigen-antibody-complement complexes (EAC'); the complement component involved has been shown to be a modified C3 (4) . Cells of the monocyte-macrophage series also play an important role in the immune response and they too bear a receptor for EAC' which is similar to the B lymphocyte receptor (5) . In some species the EAC' receptor of monocytes can be distinguished from the EAC' receptor of B lymphocytes because of the requirement of the former for the Mg"+ ion for the attachment of EAC'; in humans however, the requirement for the Mg++ ion does not distinguish (6) the EAC' receptor of monocytes from the EAC' receptor of B lymphocytes. In addition, monocytes and macrophages bear a receptor for IgG; this receptor is detected by using red cell-IgG complexes (EA) (7). This monocyte EA receptor is not found on normal lymphocytes or on lymphocytes stimulated with phytomitogens in vitro (8) . (12) . Hence, both the CLL lymphocyte and the Burkitt lymphoma cell line possess some of the properties of the B lymphocyte population. Studies from our laboratory have demonstrated the lymphocyte EAC' receptor on the L2C lymphatic leukemia cell of the guinea pig (13) and the monocyte EA receptor on a number of mouse leukemias and lymphomas (14) . In the present report, we examine the cells of 15 Human lymphoblastoid cell lines have been derived from patients with a variety of hematological disorders as well as from normal individuals. The cell lines obtained from patients and from normal individuals are indistinguishable in terms of morphology, presence of EB virus, or presence and secretion of immunoglobulin (19) . Morphologically, these cell lines are characterized by a heterogeneity of cell type; they are predominantly lymphoblasts, but also contain small numbers of plasmacytoid cells and macrophage-like cells. In the present study, we have demonstrated that 12 of the 19 cell lines studied bear the receptor for EAC' which is found on B lymphocytes; two of the cell lines bear both the EAC' and EA receptors and thus resemble the monocyte. Five of the cell lines did not bind EAC' or EA. There was apparently no relationship in this study between the disease of the patient and the characteristics of the cell line obtained from the patient. For example, plasma cells are known (4) not to possess the EAC' receptor; however, two of the cell lines derived from patients with multiple myeloma (Im-9, Im-10) demonstrated binding of EAC'. This lack of relationship is not unexpected since out of the large number of cell lines available for study, there are only two (20, 21) well-documented lines with a clear relationship between the properties of the cell line and the clinical state of the individual from whom these lines were obtained.
Of additional interest is the observation that no correlation could be seen between the secretion of immunoglobulin and the presence of the EAC' receptor. However, the B lymphocyte which bears immunoglobulin may not secrete detectable quantities of immunoglobulin. Conversely, the secretion of immunoglobulin by those cell lines which do not bear the EAC' receptor may be due to the presence of a small number of plasmacytoid cells which secrete immunoglobulin but do not bear the EAC' receptor. Cell line Raji which we have found to bear the EAC' receptor has recently 'Pincus, S., C. Bianco, and V. Nussenzweig. Submitted for publication. been shown to lack any cell associated immunoglobulin by a highly sensitive Farr technique (22) . This finding suggests that the receptor for EAC' on the normal B lymphocyte is not surface immunoglobulin. Perhaps the Raji cell line is derived from lymphocytes at a stage of differentiation when they do not bear surface immunoglobulin, but do bear the EAC' receptor.
The cells of the four patients with acute lymphatic leukemia did not show rosette formation with EAC'. The leukemic cell populations and the cell lines which did not bind EAC' or EA may represent populations of cells which are derived from T lymphocytes of from undifferentiated stem cells which do not bear these receptors. Studies' of mouse leukemias and lymphomas have shown that some bear the 8-iso-antigen and are therefore probably derived from T lymphocytes. The cells from only a small number of patients with myeloid leukemias were studied and they also did not demonstrate binding of EAC'. Since receptors for both EAC' and EA have also been described on some polymorphonuclear cells (5), more cases of myeloid leukemia should be investigated for the presence of these receptors. In fact, Nishioka (23) has reported that the cells from some chronic myelogenous leukemia patients do bind EAC'.
Our results differ from those of Michlmayr and Huber (24) who were unable to detect the EAC' receptor on CLL cells and from Nishioka (23) who was unable to detect the EAC' receptor on a large number of Burkitt lymphoma lines. Michlmayr and Huber demonstrated that 20% of normal peripheral blood lymphocytes bore the EAC' receptor, yet most of the cases of CLL studied demonstrated a lower number of EAC'-binding cells. A number of possible explanations can be offered for this discrepancy. First, the higher number of EAC'-positive cells in normal human peripheral blood reported by these investigators as compared with our study may be due to the presence in their preparations of significant numbers of monocytes or polymorphonuclear leukocytes which can form rosettes with IgM EAC' in the presence of 0.01 M EDTA. Second, the most likely explanation for their failure to find CLL cells binding EAC' is their use of human serum diluted 1/40 or 1/80 as a source of complement. In our study, mouse serum which is not lytic was used at a concentration of 1/10 as the source of complement. Although no detailed study of the Cs reactivity on a molecular basis in different species is available, it is possible that a 1/40 or 1/80 dilution of human serum supplies fewer reactive C3 molecules than a 1/10 dilution of mouse serum. In his studies of cell lines 'Shevach, E. M., J. Stobo, and I. . Immunoglobulin and 0 bearing murine leukemias and lymphomas. J. Immunol. 108: 1146.
Nishioka used (23) 300 immune adherence U of guinea pig Ca per sheep erythrocyte to prepare the EAC' complexes. From his earlier studies (25) in which a direct comparison of C3 hemolytic units and immune adherence units is made, it appears that 300 immune adherence U are equivalent to a 1/1000 dilution of guinea pig serum. Thus, here again the number of CG sites may have been insufficient for formation of rosettes.
Further detailed study of the lymphocytes and monocytes from patients with a wide variety of malignant, infectious, and immunologic diseases for both qualitative and quantitative deficiencies of the immunoglobulin and complement receptors as well as the B or T cell origin of their lymphocytes should prove rewarding. Indeed, a deficiency of the monocyte EA receptor has recently been reported in some patients with the Wiskott-Aldrich syndrome (26) .
